Oncology Treatments during the COVID-19 Pandemic in Israel : the ONCOR Study
BACKGROUND: The increased susceptibility of cancer patients to coronavirus disease-2019 (COVID-19) infections and complications calls for special precautions while treating cancer patients during COVID-19 pandemics. Thus, oncology departments have had to implement a wide array of prevention measures.
OBJECTIVES: To address issues associated with cancer care during the COVID-19 pandemic and to assess the implementation of measures aimed at containment of COVID-19 diffusion while allowing continuation of quality cancer care.
METHODS: A national survey among oncology departments in Israel was conducted between 12 April 2020 and 14 April 2020. Eighteen heads of hospital-based oncology departments completed a self-report questionnaire regarding their institute's preparedness for treatment of cancer patients during the COVID-19 pandemic.
RESULTS: In this national survey, prevention measures against COVID-19 spread were taken prior to patients' arrival and at arrival or while staying in the departments. Most participants (78-89%) reported using a quick triage of patients and caregivers prior to their entrance to the oncology units, limiting the entrance of caregivers, and reducing unnecessary visits to the clinic. Switching to oral therapies rather than intravenous ones when possible was considered by 82% and shortage in personal protective equipment was reported by five (28%) heads of oncology departments. Some differences between large and small/medium sized medical centers were observed regarding issues related to COVID-19 containment measures and changes in treatment.
CONCLUSIONS: Oncology departments in Israel were able to prepare and adapt their services to guidelines and requirements related to the COVID-19 pandemic with little harm to their treatment capacity.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
The Israel Medical Association journal : IMAJ - 23(2021), 12 vom: 26. Dez., Seite 759-765 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hirsh-Yechezkel, Galit [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.01.2022 Date Revised 03.01.2022 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM33490806X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33490806X | ||
| 003 | DE-627 | ||
| 005 | 20231225224714.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1116.xml |
| 035 | |a (DE-627)NLM33490806X | ||
| 035 | |a (NLM)34954913 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hirsh-Yechezkel, Galit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oncology Treatments during the COVID-19 Pandemic in Israel |b the ONCOR Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2022 | ||
| 500 | |a Date Revised 03.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The increased susceptibility of cancer patients to coronavirus disease-2019 (COVID-19) infections and complications calls for special precautions while treating cancer patients during COVID-19 pandemics. Thus, oncology departments have had to implement a wide array of prevention measures | ||
| 520 | |a OBJECTIVES: To address issues associated with cancer care during the COVID-19 pandemic and to assess the implementation of measures aimed at containment of COVID-19 diffusion while allowing continuation of quality cancer care | ||
| 520 | |a METHODS: A national survey among oncology departments in Israel was conducted between 12 April 2020 and 14 April 2020. Eighteen heads of hospital-based oncology departments completed a self-report questionnaire regarding their institute's preparedness for treatment of cancer patients during the COVID-19 pandemic | ||
| 520 | |a RESULTS: In this national survey, prevention measures against COVID-19 spread were taken prior to patients' arrival and at arrival or while staying in the departments. Most participants (78-89%) reported using a quick triage of patients and caregivers prior to their entrance to the oncology units, limiting the entrance of caregivers, and reducing unnecessary visits to the clinic. Switching to oral therapies rather than intravenous ones when possible was considered by 82% and shortage in personal protective equipment was reported by five (28%) heads of oncology departments. Some differences between large and small/medium sized medical centers were observed regarding issues related to COVID-19 containment measures and changes in treatment | ||
| 520 | |a CONCLUSIONS: Oncology departments in Israel were able to prepare and adapt their services to guidelines and requirements related to the COVID-19 pandemic with little harm to their treatment capacity | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Chetrit, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Ben Avraham, Sivan |e verfasserin |4 aut | |
| 700 | 1 | |a Agbarya, Abed |e verfasserin |4 aut | |
| 700 | 1 | |a Yakobson, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Asna, Noam |e verfasserin |4 aut | |
| 700 | 1 | |a Bar-Sela, Gil |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Aharon, Irit |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Baruch, Noa Efrat |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Raanan |e verfasserin |4 aut | |
| 700 | 1 | |a Brenner, Ronen |e verfasserin |4 aut | |
| 700 | 1 | |a Gottfried, Maya |e verfasserin |4 aut | |
| 700 | 1 | |a Paluch-Shimon, Shani |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeffer, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Popovtzer, Aron |e verfasserin |4 aut | |
| 700 | 1 | |a Ryvo, Larisa |e verfasserin |4 aut | |
| 700 | 1 | |a Semenisty, Valeriya |e verfasserin |4 aut | |
| 700 | 1 | |a Shai, Ayelet |e verfasserin |4 aut | |
| 700 | 1 | |a Shulman, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Zidan, Jamal |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Ido |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Israel Medical Association journal : IMAJ |d 1999 |g 23(2021), 12 vom: 26. Dez., Seite 759-765 |w (DE-627)NLM106585835 |x 1565-1088 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:12 |g day:26 |g month:12 |g pages:759-765 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 12 |b 26 |c 12 |h 759-765 | ||